Hormonal birth control and pregnancy: A comparative analysis of thromboembolic risk

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 912-916

  Wilks, John F ^a  

^a Drug Info Centre of Western Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; GONANE DERIVATIVE; LEVONORGESTREL; MESTRANOL; ORAL CONTRACEPTIVE AGENT;

BIRTH CONTROL; BLOOD CLOTTING; CARDIOVASCULAR RISK; CONTRACEPTION; DEEP VEIN THROMBOSIS; DRUG SAFETY; HUMAN; MEDICAL SOCIETY; MEDICOLEGAL ASPECT; MORTALITY; NOTE; PREGNANCY; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; CONTRACEPTIVES, ORAL, HORMONAL; FAMILY PLANNING SERVICES; FEMALE; HUMANS; PREGNANCY; RISK FACTORS; THROMBOEMBOLISM;

EID: 0038485906     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C340     Document Type: Note

References (32)

1. Grimes DA. Venous thromboembolism and desogestrel- or gestodenecontaining combination oral contraceptives: what are the facts? Contraception Rep 1996;7(1)1-15.
2. Farmer R. Safety of modern oral contraceptives (letter). Lancet 1996;347:259.
3. Persaud R. Oral contraceptives and venous thromboembolism (letter). Lancet 1995;346:1430-1.
4. Francombe H. Pill's risk not to be taken lightly: study. Aust Doctor 2000; (June 30):3.
5. New Zealand Ministry of Health: media release March 3, 1999. Ministry advice on pill consistent, consensual and commonsense. www.moh. govt.nz (accessed 2003 Feb 5).
6. Mishell DR Jr. Cardiovascular risks: perception versus reality. Contraception 1999;59(1 suppl):215-45.
7. Grimes DA. Desogestrel- and gestodene-containing combination OC's and venous thromboembolism: where are we now? Contraception Rep 1999;10(1):4-8.
8. McPherson K. Third generation oral contraception and venous thromboembolism. BMJ 1996;312:68-9.
9. Grant EC. Dangers of suppressing menstruation (letter). Lancet 2000;356:513.
10. Ashraf H. UK high court dismisses risk of VTE in "pill" test case. Lancet 2002;360:391.
11. Skegg CG. Pitfalls of pharmacoepidemiology. BMJ 2000;321:1171-2.
12. van Heteren G. Wyeth suppresses research on pill. Programme claims (letter). BMJ 2001;322:571.
13. Brock P. Wyeth responds to news story on oral contraceptives and DVT (letter). BMJ 2001;322:1605.
14. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. Contraception 1998;57:291-301.
15. Lawrenson RA, Whalley A, Simpson E, Farmer RDT. DoH seems to have underestimated incidence of venous thromboembolism in users of combined oral contraceptives (letter). BMJ 1999;319:387.
16. Weiss G. Risk of venous thromboembolism with third-generation contraceptives: a review. Am J Obstet Gynecol 1999;180:(2 pt 2):S295-301.
17. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-65.
18. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997;177:887-91.
19. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127-8.
20. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism and oral contraceptives. Lancet 1999;354:1469-70. [erratum 1999;354:1478].
21. Vandenbroucke JP, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1535.
22. Spitzer WO, Lewis MA. Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;31;83-8.
23. Hague WM, North RA, Gallus AS, Walters BN, Orlikowski C, Burrows RF, et al. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001;175:258-63.
24. Rosing J, Middledorp S, Curvers J, Christella M, Thomassen LGD, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999;354:2036-40.
25. Suissa S, Blais L, Spitzer WO, Cusson, J, Lewis M, Heinemann L. Firstever use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6.
26. Farmer RDT, Williams TJ, Simpson EL, Nightingale AL. Effect of the 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ 2000;321:477-9.
27. Australian Adverse Drug Reactions Bulletin. vol 21, no. 2, June 2002. www.health.gov.au/tga/docs/html/aadrbltn/aadr0206.htm#ven (accessed 2003 Feb 5).
28. Sorensen MB, Collins P, Ong PJL, Webb CM, Hayward CS, Asbury EA, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646-51.
29. Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception 1999;59:25-9.
30. Larimore WL, Stanford JB. Postfertilization effects of oral contraceptives and their relationship to informed consent. Arch Family Med 2000;9:126-33.
31. A prospective multi-centre trial of ovulation method of natural family planning. II. The effectiveness phase. Fert Steril 1981;36:591-8.
32. Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:56-63.